Multiple Myeloma

Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses treatment options for transplant eligible patients with multiple myeloma.

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School, discusses treatment approaches targeting mutational burden in multiple myeloma.

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.

Paul G. Richardson, MD, highlights the many promising agents that have emerged in relapsed/refractory multiple myeloma in recent years, remaining challenges, and hope for continued progress.

Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the treatment of patients with newly diagnosed myeloma.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory myeloma.

Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.

Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain.

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses anticipated developments in the field of multiple myeloma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted positive opinions to 2 triplet regimens with immunomodulatory agents for patients with multiple myeloma.

A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.

A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.